Biggest plus: Strongest FDA black-box screen in the compounded category captures personal AND family history for MTC and MEN-2
Experience the Benefits of Bombshell Beauty IV Drip The Bombshell Beauty IV drip from Rev(IV)al Hydration offers powerful benefits to help you achieve healthier, glowing skin
Other information Content details Last updated on 28 Jul 2026 | 01:04 AM (IST) Manufacturer details Name: A)Growequal Address: A)D-15, Sahjanand Business Park, Odhav Ring, Nikol, Ahmedabad-382350, India P&ISO 17025:2017 certified company) Marketer details Name: Nutraceum Inc Address: 308, Sanskar Height, 150 Feet Ring Road, Mavdi, Rajkot, Gujarat, 360004 Vendor Details Country of origin: India A licensed vendor partner from your nearest location will deliver Nutrasium 8 in 1 L-Glutathione 600 mg
doi: 10.1089/neu.2011.1983
GHK-Cu is not FDA approved as a drug for skin repair, anti-aging, injection, or any therapeutic use, and researchers exploring administration should review our guide on where to inject GHK-Cu for the practical considerations
: JAMA Psychiatry study highlights (semaglutide in schizophrenia spectrum disorders): Studied adults with schizophrenia spectrum disorders treated with clozapine or olanzapine, two antipsychotics strongly linked to weight gain and metabolic syndrome Participants were randomized to receive semaglutide (GLP-1 receptor agonist) vs placebo, in addition to usual psychiatric care Significant weight loss was observed in the semaglutide group compared with placebo Improved glycemic control including reductions in HbA1c and fasting glucose, even in early metabolic dysregulation Beneficial effects seen early, suggesting potential for prevention of diabetes rather than late treatment Semaglutide was generally well tolerated, with no worsening of psychotic symptoms Addresses a major unmet need, people with serious mental illness die earlier largely due to cardiometabolic disease Supports the role of GLP-1 receptor agonists as an adjunct treatment to mitigate antipsychotic-induced metabolic harm Bottom line: A promising strategy to reduce weight, diabetes risk, and long-term cardiovascular mortality in patients on high-risk antipsychotics
